FULC
Fulcrum Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.76
−0.27%Aug 19, 2026, 17:14 UTC
Kahn Swick & Foti, LLC is investigating the proposed merger of Fulcrum Therapeutics, Inc. and Slate Medicines, Inc., under which Fulcrum shareholders are expected to own 5.0% of the combined company.
Source:Aug 17, 2026, 11:00 UTC
Fulcrum Therapeutics and Slate Medicines announced a merger agreement to combine and operate as Slate Medicines, focusing on advancing next-generation migraine therapies.
Aug 10, 2026, 16:32 UTC
Kaplan Fox & Kilsheimer LLP announced an investigation into potential securities violations by Fulcrum Therapeutics, Inc. and encouraged investors who suffered losses to contact the firm.
Aug 10, 2026, 00:00 UTC
Greg Tourangeau departed as Vice President, Finance and principal accounting officer of Fulcrum Therapeutics, Inc. by mutual agreement, effective 2026-08-07.
Jun 4, 2026, 14:22 UTC
Fulcrum Therapeutics discontinued its lead experimental drug pociredir for sickle cell disease.
Source:Jun 2, 2026, 19:47 UTC
Fulcrum Therapeutics announced it will explore strategic alternatives including a possible merger, acquisition, or sale of assets.
Source:Jun 1, 2026, 20:05 UTC
Fulcrum Therapeutics discontinued its pociredir program in sickle cell disease following FDA feedback about secondary malignancies observed with Tazverik and its global withdrawal.